Sitagliptin Reduces Hyperglycemia and Increases Satiety Hormone Secretion More Effectively When Used with a Novel Polysaccharide in Obese Zucker Rats 1–3

Raylene A. Reimer,4,5* Gary J. Grover,6,7 Lee Koetzner,6 Roland J. Gahler,8 Prateek Juneja,9,10 Michael R. Lyon,9,10 and Simon Wood6,10

4Faculty of Kinesiology, and 5Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Calgary, Calgary, AB, Canada; 6Department of Pharmacology, Product Safety Labs, Dayton, NJ; 7Department of Physiology and Biophysics, Robert Wood Johnson Medical School, Piscataway, NJ; 8Factors Group of Nutritional Companies Inc. R and D, Burnaby, BC, Canada; 9Canadian Centre for Functional Medicine, Coquitlam, BC, Canada; and 10University of British Columbia, Food, Nutrition and Health Program, Vancouver, BC, Canada

Abstract

The novel polysaccharide (NPS) PolyGlycopleX (PGX) has been shown to reduce glycemia. Pharmacological treatment with sitagliptin, a dipeptidyl peptidase 4 (DPP4) inhibitor, also reduces glycemia by increasing glucagon-like- peptide-1 (GLP-1). Our objective was to determine if using NPS in combination with sitagliptin reduces hyperglycemia in Zucker diabetic fatty (ZDF) rats more so than either treatment alone. Male ZDF rats were randomized to: 1) cellulose/vehicle [control (C)]; 2) NPS (5% wt:wt)/vehicle (NPS); 3) cellulose/sitagliptin [10 mg/kg · d] (S); or 4) NPS (5%) + S (10 mg/kg · d) (NPS + S). Glucose tolerance, adiposity, satiety hormones, and mechanisms related to DPP4 activity and hepatic and pancreatic histology were examined. A clinically relevant reduction in hyperglycemia occurred in the rats treated with NPS + S (P = 0.001) compared with NPS and S alone. Blood glucose, measured weekly in fed and feed-deprived rats and during an oral glucose tolerance test, was lower in the NPS + S group compared with all other groups (all P = 0.001). At wk 6, glycated hemoglobin was lower in the NPS + S group than in the C and S (P = 0.001) and NPS (P = 0.06) groups. PGX (P = 0.001) and S (P = 0.014) contributed to increased lean mass. Active GLP-1 was increased by S (P = 0.001) and GIP was increased by NPS (P = 0.001). Plasma DPP4 activity was lower in the NPS + S and S groups than in the NPS and C groups (P = 0.007). Insulin secretion and β-cell mass was increased with NPS (P < 0.05). NPS alone reduced LDL cholesterol and hepatic steatosis (P < 0.01). Independently, NPS and S improve several metabolic outcomes in ZDF rats, but combined, their ability to markedly reduce glycemia suggests they may be a promising dietary/pharmacological co-therapy for type 2 diabetes management. J. Nutr. 142: 1812–1820, 2012.

Introduction

The health and economic toll of obesity continues to rise, seemingly unabated, worldwide (1). There are currently an estimated 1.5 billion overweight and obese individuals globally (2). The NIH has recommended that combined lifestyle and pharmacological therapy be used for all obese individuals or overweight individuals with at least one co-morbidity (3). There are currently a limited number of dietary and pharmacological co-therapies that have been sufficiently evaluated to move this recommendation forward.

Sitagliptin (S)11 is an oral antidiabetic medication that blocks dipeptidyl peptidase 4 (DPP4), the enzyme responsible for the rapid degradation of active glucagon-like peptide-1 (GLP-1) (4),

11 Abbreviations used: AST, alanine aminotransferase; C, control; DPP4, dipeptidyl peptidase 4; GIP, glucose-dependent insulinotropic polypeptide; GIPr, glucose-dependent insulinotropic polypeptide receptor; GLP-1, glucagon-like peptide 1; HbA1c, glycated hemoglobin; InsAUC15:GluAUC20, ratio of insulin AUC:glucose AUC from 0 to 20 min of the oral glucose tolerance test; InsAUC60:GluAUC60, ratio of insulin AUC:glucose AUC from 0 to 60 min of the oral glucose tolerance test; InsAUC120:GluAUC120, ratio of insulin AUC:glucose AUC from 0 to 120 min of the oral glucose tolerance test; NPS, novel polysaccharide; OGTT, oral glucose tolerance test; PGX, PolyGlycopleX; PYY, peptide tyrosine tyrosine; S, sitagliptin; WAT, white adipose tissue; ZDF, Zucker diabetic fatty.
In addition to exerting potent insulinotropic activity, GLP-1 also reduces food intake, suppresses glucagon secretion, slows gastric emptying, and stimulates β-cell regeneration (5). DPP4 inhibitors are orally active and can inhibit >90% of plasma DPP4 activity over a 24-h period (6). Inhibition of DPP4 improves insulin sensitivity and results in reduced blood glucose concentrations (7,8). S specifically has been approved by the FDA, Health Canada, and the European Commission as a single therapy for the treatment of diabetes and it can be effectively combined with metformin or glitazone (9,10).

Dietary fibers have numerous health benefits, including lowering plasma cholesterol levels, reducing hyperglycemia, enhancing the secretion of satiety hormones, and improving bowel function (11). Some dietary fibers enhance the secretion of GLP-1 and another anorexigenic gut hormone, peptide YY (PYY) (12–16). We have previously shown that the highly viscous functional fiber, PolyGlycopleX (PGX) (α-D-glucuronon-α-D-mannan-β-D-mannan-β-D-gluco α-L-gulurono-β-D-mannuron, β-D-gluco-β-D-mannan; InovoBiologic) novel polysaccharide (NPS) reduces hyperglycemia and increases GLP-1 secretion in obese Zucker diabetic fatty (ZDF) rats (17). We have also demonstrated that NPS increases the anorexigenic hormone PYY in healthy humans (18) and it decreases hunger and promotes satiety in obese humans undergoing a low-energy diet regime (19). Whether or not combining the glycemia-lowering actions of NPS with the known GLP-1–protective and hypoglycemic actions of sitagliptin improves glucose tolerance in rats is not known.

Our objective was to determine the effects of the combined treatment of NPS with S on glucose tolerance in obese ZDF rats. Secondary outcomes were measured to gain insight into the mechanisms of NPS and S actions and included body composition, satiety hormone secretion, pancreatic islet and liver histology, and DPP4 activity.

Methods

Rats and treatments. Ethical approval for the experimental protocol was granted by the Eurofins Institutional Animal Use and Care Committee and all procedures conformed to the Guide for Care and Use of Laboratory Animals. Forty-four male ZDF/Crl-Lep+/+ rats (ZDF) were obtained from Charles River at 9 wk of age and individually housed in a temperature-18–22°C and humidity-controlled (44–68%) room with a 12-h-light/-dark cycle. Water and feed were provided ad libitum. Male ZDF rats were selected as representing a good model of obesity with comorbid type 2 diabetes and reduced insulin sensitivity (20,21). Following 4 d of acclimation, rats were randomly assigned to 1 of 4 groups: 1) control [cellulose fiber/vehicle (C)]; 2) NPS [5% wt : wt/vehicle (NPS)]; 3) cellulose/S [10 mg/kg · d] via oral gavage (S); or 4) NPS [5%] + S [10 mg/kg · d] (NPS+S). There were n = 11 rats/group. The NPS was PGX (InovoBiologic). NPS was shipped to Research Diets for incorporation into a high-fat rodent diet (D12451) at 5% wt : wt (Supplemental Table 1). Cellulose was selected as the insoluble reference fiber that is considered to be inert (22). S phosphate monohydrate (JANUVIA, Merck and Co) was obtained by prescription at a pharmacy in Dayton, NJ and prepared in water and given daily by gavage (10 mg/kg) in the morning.

Continuous study measures. Body weight was measured once each week. Food intake, accounting for spillage, was measured 3 times/wk. Blood glucose was measured weekly using a Bayer Ascensia Elite Glucometer (Bayer Health Care). The blood was collected via tail nick following S administration: one sample when food was present for the previous 24 h and one sample was collected on another day when food was not available overnight (16 h feed deprived).

Oral glucose tolerance tests. Three days before the end of the study and following 16 h of feed deprivation, a baseline blood sample was collected. S was administered prior to the baseline blood draw. A 1-g/kg dose of glucose was given via oral gavage and subsequent blood samples collected via tail nick at 10, 20, 30, 60, and 120 min. Blood glucose concentrations were immediately determined with a glucometer. A second and separate oral glucose tolerance test (OGTT) was performed for satiety hormone analysis on the final day of the study. Following overnight feed deprivation and morning S administration, a baseline blood sample was collected. Glucose (2 g/kg) was given via gavage and subsequent blood samples taken at 15, 30, 60, and 90 min via tail nick. Blood was collected with the addition of dipyrotnin-A (0.034 g/L blood; MP Biomedicals), Sigma protease inhibitor (1 g/L blood; Sigma Aldrich), and Roche Pefabloc (1 g/L of blood; Roche). Plasmas were stored at −80°C until later analysis. To assess the increment in insulin secretion triggered by an increment in plasma glucose (termed the insulogenic index), we calculated insulin response for the early and total secretory phases as follows: the ratio of insulin AUC glucose AUC from 0 to 15 min of the OGTT (InsAUC15 : GluAUC15) correlates with early-phase insulin release during the OGTT) and the ratio of insulin AUC : glucose AUC from 0 to 120 min of the OGTT (InsAUC120 : GluAUC120) correlates with second-phase and total insulin release during the OGTT). In a human validation study (23), InsAUC120 : GluAUC120 was highly correlated with first-phase insulin secretion. In rodents, however, peak insulin secretion occurs between 10 and 20 min (24) and insulin secretion at 15 min was therefore used for calculations. The composite insulin sensitivity index (CISI), which takes into account glucose excursion and AUC, was also calculated as previously described (17). Higher scores represent improved insulin sensitivity.

Lipid determination, plasma DPP4 activity, and clinical chemistry. At the termination of the study, a blood sample was collected via retro-orbital bleed under isoflurane anesthesia. Serum was analyzed for lipid concentrations (total, LDL, HDL cholesterol, and TG) using an analyzer (Polymer Technology Systems CardioChek). DPP4 activity in plasma was measured according to Kirino et al. (25). A clinical chemistry panel was analyzed in plasma, including blood urea nitrogen, glucose, electrolytes, creatinine, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase (AST), and bilirubin (direct + indirect).

Tissue collection and necropsy. At the termination of the study, following overnight feed deprivation and regular S treatment in the morning, rats were overanesthetized with isoflurane and a blood sample was collected via cardiac puncture. A section of the distal ileum, one kidney, and one liver lobe were snap-frozen for later DPP4 mRNA analysis. The pancreas and one liver lobe were fixed in 10% neutral buffered formalin for later processing. One liver lobe was snap-frozen for determination of lipid content with Sudan Black staining. The pancreas was transferred to 70% ethanol after 24 h. Tissues were processed and embedded in paraffin. The liver was sectioned (3 μm) and stained with hematoxylin and eosin or immunohistochemically stained with a mouse antibody against rat insulin (1:300, Cell Signaling Technology) according to previous work (26). The histopathology scoring was 0, within normal limits; 1, minimal; 2, mild; 3, moderate; 4, marked; and 5, severe.

Biochemical analysis. A Rat Gut Hormone Multiplex kit (Millipore) was used to measure insulin, active GLP-1, active amylin, active ghrelin, leptin, total PYY, and total GIP according to our previous work (27,28). Glycated hemoglobin (HbA1c) was measured in blood using a clinical analyzer (Bayer DCA 2000).

Statistical analysis. All data are presented as mean ± SEM. A 2-way ANOVA was used to determine the main effects of diet (NPS vs. cellulose) and drug (S vs. vehicle) and their interaction. When a significant interaction effect was identified, a 1-way ANOVA with Tukey’s multiple comparison post hoc test was used to identify differences between groups. For parameters where repeated measurements were taken over time (i.e., body weight, glucose, HbA1c, and satiety hormones), a 2-way repeated-measure ANOVA was performed with between-subject factor (treatment of 4 levels) and within-subject factor (time). Noninterval data (e.g., histology scores) were analyzed by

Novel polysaccharide and sitagliptin co-therapy 1813

Downloaded from https://academic.oup.com/jn/article-abstract/142/10/1812/4630664 by guest on 09 February 2019
Results

NPS and S effects on food intake and body weight. Both NPS (P = 0.001) and S (P = 0.001) contributed to changes in food intake (Table 1). Rats fed NPS had 20% lower food intake than those fed cellulose and rats given S had 11% lower food intake than vehicle. Body weight increased with time (P = 0.001) (Supplemental Fig. 1). Diet affected final body weight (P = 0.027) and weight gain (P = 0.011), with rats fed NPS having greater overall weight gain and higher final body weight (Table 1). Lean mass was influenced by NPS (P = 0.001) and S (P = 0.014), with greater lean mass in rats treated with NPS compared with those treated with cellulose and in rats treated with S compared with vehicle. Fat mass (expressed as grams or percentage of body fat) and bone mineral density did not significantly differ between groups.

Glycemic response. Both time (P = 0.001) and treatment (P = 0.001) and their interaction (P = 0.001) affected blood glucose concentrations measured weekly in feed-deprived rats (Fig. 1A). Rats treated with NPS+S had lower blood glucose than all other groups at 6 wk (P < 0.01) lower than C and S at 3, 4, and 5 wk (P < 0.02) and lower than C at every week after baseline (P < 0.003). Given that NPS is highly viscous and affects intestinal glucose absorption when present in the lumen, we also measured blood glucose concentrations in fed rats once each week. Both time (P < 0.002) and treatment (P = 0.001) and their interaction (P = 0.001) affected blood glucose concentrations in the fed state (Fig. 1B). At 4, 5, and 6 wk, the NPS+S rats had lower blood glucose than all other groups (P < 0.002). From 2 wk onwards, rats treated with NPS+S had lower blood glucose than the C and S rats (P = 0.01). Similarly, there was an effect of time (P = 0.001) and treatment (P = 0.001) and their interaction (P = 0.001) for repeated HbA1c measurements (Fig. 1C). At 3 wk, the NPS+S rats had lower HbA1c than C rats (P = 0.01) and at 6 wk, the NPS+S group was lower than C and S groups (P = 0.001) and showed a trend to be lower than the NPS group (P = 0.06).

Interactive effects on glucose and satiety hormones during OGTT. There was an effect of time (P < 0.001) for all satiety hormones at the final OGTT except ghrelin (Fig. 2). Treatment influenced insulin secretion (P = 0.038) such that the NPS group was higher than the C group (P = 0.049) (Fig. 2A). Treatment (P = 0.001) and its interaction with time (P = 0.001) affected GIP during the OGTT (Fig. 2B). At 15, 30, and 60 min, the NPS group had higher GIP than all other groups (P < 0.04). At 15 min, the S (P = 0.046) and NPS+S (P = 0.04) rats had higher active GLP-1 compared with C rats (Fig. 2C). At 30 min, the S group had higher GLP-1 than the C (P = 0.003) and NPS (P = 0.04) groups. Leptin was affected by time (P = 0.01) but not the treatments (P = 0.14) (Fig. 2D). NPS increased 0, 15, and 30 min amylin concentrations during the OGTT compared with C (P < 0.038) (Fig. 2E). The NPS+S rats also had higher amylin at 15, 30, and 60 min compared with the C and S groups (P < 0.05). Blood glucose was also measured following an oral glucose load 3 d before the end of the study (Fig. 2F). Time (P = 0.001), treatment (P = 0.001), and their interaction (P = 0.001) affected glucose, with a marked reduction occurring in the NPS+S group compared with all other groups throughout the 120-min OGTT. There was an effect of time (P = 0.001) for PYY and no significant differences in ghrelin (data not shown).

The AUC during the OGTT was calculated for all satiety hormones and glucose. The AUC for insulin increased with NPS compared with cellulose (P = 0.009) (Table 2). Both diet (P = 0.003) and drug (P = 0.001) and their interaction affected the GIP AUC, with the NPS group having higher AUC than all other groups (P < 0.002). Active GLP-1 increased with S compared with vehicle (P = 0.001). Amylin, co-secreted with insulin, was affected by NPS (P = 0.001) and S (P = 0.039) such that NPS and S independently increased the AUC. The glucose AUC was reduced with NPS (P = 0.009) and S (P = 0.003). Despite a 50% reduction in glucose AUC in NPS+S compared with C and an ~32% reduction in AUC compared with NPS and S alone, the interaction between NPS and S was not significant (P = 0.7), although probably physiologically relevant.

Surrogate indexes of first-phase and total insulin secretion and insulin sensitivity. Given that the β-cell responds to increments in plasma glucose concentration with an increment in plasma insulin secretion (29), we calculated the insulin response for both the early (0–15 min) and total secretory phases (0–120 min). Both the InsAUC15 : GluAUC20 and InsAUC120 : GluAUC120 ratios were increased by NPS (P = 0.001) but not S (P = 0.3) or their interaction (P = 0.9) (Table 2). The C ISI scores did not significantly differ among the groups (Table 2).

Changes in DPP4 activity. DPP4 activity in the plasma was affected by NPS (P = 0.001), S (P = 0.001), and their interaction (P = 0.007) (Fig. 3). C had higher plasma DPP4 activity than all other groups (P = 0.001). In the liver, DPP4 activity was reduced

### TABLE 1

<table>
<thead>
<tr>
<th>Treatment</th>
<th>C</th>
<th>NPS</th>
<th>S</th>
<th>NPS+S</th>
<th>Two-way ANOVA P values</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diet</td>
<td>Drug</td>
<td>Diet × drug</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Food intake, g/d</td>
<td>26 ± 0.5</td>
<td>20 ± 0.6</td>
<td>23 ± 0.7</td>
<td>18 ± 0.5</td>
<td>0.001</td>
</tr>
<tr>
<td>Final body weight, g</td>
<td>405 ± 17.4</td>
<td>431 ± 9.60</td>
<td>411 ± 16.1</td>
<td>441 ± 5.32</td>
<td>0.027</td>
</tr>
<tr>
<td>Total weight change, g</td>
<td>106 ± 13.8</td>
<td>128 ± 7.10</td>
<td>111 ± 12.5</td>
<td>139 ± 4.21</td>
<td>0.011</td>
</tr>
<tr>
<td>Fat mass, g</td>
<td>218 ± 13.3</td>
<td>228 ± 9.1</td>
<td>213 ± 9.81</td>
<td>224 ± 7.83</td>
<td>0.29</td>
</tr>
<tr>
<td>Lean mass, g</td>
<td>113 ± 3.5</td>
<td>130 ± 3.84</td>
<td>123 ± 5.40</td>
<td>142 ± 4.02</td>
<td>0.001</td>
</tr>
<tr>
<td>Percent fat, %</td>
<td>53.5 ± 1.14</td>
<td>52.7 ± 1.28</td>
<td>51.8 ± 0.92</td>
<td>50.8 ± 1.39</td>
<td>0.48</td>
</tr>
<tr>
<td>Bone mineral density, g/cm²</td>
<td>0.167 ± 0.001</td>
<td>0.168 ± 0.002</td>
<td>0.169 ± 0.003</td>
<td>0.169 ± 0.003</td>
<td>0.83</td>
</tr>
</tbody>
</table>

1 Values are means ± SEM, n = 8–11. C, control; NPS, novel polysaccharide; NPS+S, novel polysaccharide and sitagliptin; S, sitagliptin; ZDF, Zucker diabetic fatty.
Changes in serum lipids and hepatic biomarkers. Total cholesterol was affected by diet \((P = 0.001)\) such that rats consuming NPS had lower cholesterol than those consuming cellulose (Table 3). LDL concentrations were influenced by NPS \((P = 0.001)\) and S \((P = 0.01)\), wherein both NPS and S independently reduced LDL cholesterol. Concentrations of serum TG were above the detection limit of the assay for all groups except NPS+S, even following dilution, and are therefore not reliable. In the liver, hepatic steatosis was evaluated with Sudan Black staining (Table 3). There was an effect of diet for steatosis \((P = 0.013)\), wherein rats fed NPS had lower scores than those fed cellulose. Microvesicular vacuolation scores were influenced by NPS \((P = 0.033)\) and S \((P = 0.036)\), with lower pathology scores independently seen for NPS and S. Serum aspartate aminotransferase concentrations were lower with NPS compared with cellulose \((P = 0.001)\). The interaction between NPS and S \((P = 0.048)\) affected serum AST concentrations, with C rats having higher AST than NPS \((P = 0.017)\) but not S or NPS+S.

Discussion

As the rates of obesity and type 2 diabetes continue to rise worldwide, there is growing pressure to identify effective treatments to manage these diseases (30). For a number of decades, increased intake of viscous dietary fiber has been recommended for the management of type 2 diabetes due to its ability to slow glucose absorption from the small intestine (31,32). More recently, the pharmacological agent S, which prevents the degradation of GLP-1 by inhibiting DPP4, has been shown to reduce peak glucose concentrations during an OGTT and lower HbA1c (33). Our objective was to determine if combining a dietary treatment with effective glucose-lowering action with a pharmacological agent, S, would further improve glucose control over either treatment alone. Although we confirm that independent administration of NPS or S is effective at lowering food intake (both), increasing lean mass (both), reducing LDL cholesterol and hepatic steatosis (NPS), and increasing active GLP-1 (S), the combined actions of NPS and S on reducing glycemia more so than either treatment alone are significant and clinically relevant.

The chief finding of this study is the marked and significant reduction in blood glucose in ZDF rats with the combined treatment of NPS+S. We measured glucose control in 4 distinct ways, including weekly measures of blood glucose in the fed and fasted states, HbA1c, and an OGTT. All measures of glucose response showed the combined therapy to be highly effective in reducing glycemia. The interaction between NPS and S during weekly blood glucose measurements showed the combined therapy to be more effective than either treatment alone at reducing glucose, particularly fed blood glucose concentrations in the final 3 wk of the study and during an acute OGTT. The therapeutic potential of these findings is highlighted in work showing that the degree of hyperglycemia is directly associated with the incidence of microvascular and macrovascular complications (34). Reductions in fed blood glucose concentrations may be particularly relevant given the recent demonstration by Cavalot et al. (35) that cardiovascular events and all-cause mortality are predicted by postprandial blood glucose. The physical properties of NPS may make it especially effective at lowering postprandial glucose concentrations.

In ZDF rats, glucose intolerance usually develops by the age of 8 wk, followed by overt hyperglycemia by age 10–12 wk (36).
If human criteria for postprandial hyperglycemia are used (>11.1 mmol/L), all of our rats would be considered diabetic at baseline (0 wk in Fig. 1B). Rats in the C and S groups remained diabetic throughout the study. The NPS rats had lower postprandial glycemia after 1 and 2 wk of treatment but remained diabetic from 3 to 6 wk inclusive. Rats in the NPS+S group, however, had normoglycemia for all intervention weeks except for the very last week. This may reflect diminished treatment effectiveness at this late time point or possibly a greater stress response to the increased number of tests performed in the final week. If we consider the human diabetes criteria for fasting hyperglycemia (>7.1 mmol/L), all of the rats were normoglycemic at baseline. All groups would be classified as diabetic thereafter except for the NPS+S group that had fasting glucose levels <7.1 mmol/L. These results suggest that NPS+S was able to attenuate diabetes in the ZDF rat.

NPS is a novel functional fiber that is highly viscous and has high water-holding and gel-forming properties (37). Other viscous soluble fibers have been shown to improve postprandial glycemia and insulin response via a slowing of gastric emptying.

![FIGURE 2](https://academic.oup.com/jn/article-abstract/142/10/1812/4630664) Plasma insulin (A), GIP (B), GLP-1 (C), leptin (D), amylin (E), and blood glucose (F) of obese ZDF rats during an OGTT. Values are mean ± SEM, n = 8–11. Labeled means at a time without a common letter differ, P < 0.05. C, control; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; NPS, novel polysaccharide; NPS+S, novel polysaccharide and sitagliptin; OGTT, oral glucose tolerance test; S, sitagliptin; ZDF, Zucker diabetic fatty.

| Table 2 | Plasma AUC for glucose and satiety hormones of obese ZDF rats treated with NPS, S, both, or neither for 6 wk.  

<table>
<thead>
<tr>
<th>Parameter</th>
<th>C</th>
<th>NPS</th>
<th>S</th>
<th>NPS+S</th>
<th>Two-way ANOVA P values</th>
<th>Diet</th>
<th>Drug</th>
<th>Diet × drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin, pmol/L × 90 min</td>
<td>66.5 ± 12.7</td>
<td>184 ± 26.5</td>
<td>136 ± 34.3</td>
<td>178 ± 31.4</td>
<td>0.009</td>
<td>0.28</td>
<td>0.20</td>
<td></td>
</tr>
<tr>
<td>GIP, pmol/L × 90 min</td>
<td>2.9 ± 0.4</td>
<td>4.8 ± 0.1</td>
<td>2.5 ± 0.2</td>
<td>2.7 ± 0.2</td>
<td>0.003</td>
<td>0.001</td>
<td>0.012</td>
<td></td>
</tr>
<tr>
<td>GLP-1, pmol/L × 90 min</td>
<td>3.0 ± 0.2</td>
<td>3.6 ± 0.3</td>
<td>5.1 ± 0.6</td>
<td>4.6 ± 0.5</td>
<td>0.92</td>
<td>0.001</td>
<td>0.20</td>
<td></td>
</tr>
<tr>
<td>PYY, pmol/L × 90 min</td>
<td>2.2 ± 0.2</td>
<td>1.9 ± 0.2</td>
<td>2.3 ± 0.3</td>
<td>2.2 ± 0.2</td>
<td>0.29</td>
<td>0.300</td>
<td>0.64</td>
<td></td>
</tr>
<tr>
<td>Ghrelin, pmol/L × 90 min</td>
<td>1.8 ± 0.7</td>
<td>2.3 ± 0.5</td>
<td>1.7 ± 0.3</td>
<td>2.2 ± 0.4</td>
<td>0.28</td>
<td>0.80</td>
<td>0.96</td>
<td></td>
</tr>
<tr>
<td>Leptin, pmol/L × 90 min</td>
<td>158 ± 13.9</td>
<td>142 ± 13.3</td>
<td>149 ± 9.53</td>
<td>123 ± 8.12</td>
<td>0.07</td>
<td>0.23</td>
<td>0.63</td>
<td></td>
</tr>
<tr>
<td>Amylin, pmol/L × 90 min</td>
<td>2.9 ± 0.4</td>
<td>6.5 ± 0.7</td>
<td>4.9 ± 0.6</td>
<td>8.0 ± 1.0</td>
<td>0.001</td>
<td>0.039</td>
<td>0.71</td>
<td></td>
</tr>
<tr>
<td>Glucose, mmol/L × 90 min</td>
<td>723 ± 81.6</td>
<td>525 ± 57.2</td>
<td>500 ± 59.2</td>
<td>345 ± 58.1</td>
<td>0.009</td>
<td>0.003</td>
<td>0.73</td>
<td></td>
</tr>
<tr>
<td>InsAUC15:GluAUC20, pmol/mmol</td>
<td>154 ± 28.4</td>
<td>675 ± 123</td>
<td>330 ± 109</td>
<td>782 ± 180</td>
<td>0.001</td>
<td>0.30</td>
<td>0.80</td>
<td></td>
</tr>
<tr>
<td>InsAUC120:GluAUC120, pmol/mmol</td>
<td>127 ± 24.8</td>
<td>652 ± 129</td>
<td>284 ± 99.9</td>
<td>875 ± 175</td>
<td>0.001</td>
<td>0.15</td>
<td>0.84</td>
<td></td>
</tr>
<tr>
<td>C ISI score</td>
<td>0.64 ± 0.13</td>
<td>0.43 ± 0.06</td>
<td>0.55 ± 0.15</td>
<td>0.79 ± 0.13</td>
<td>0.95</td>
<td>0.26</td>
<td>0.07</td>
<td></td>
</tr>
</tbody>
</table>

1 Values are means ± SEM, n = 9–10. Labeled means without a common letter differ, P < 0.05. C, control; C ISI, composite insulin sensitivity index; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; InsAUC15:GluAUC20, ratio of insulin AUC:glucose AUC from 0 to 15 min of the oral glucose tolerance test; InsAUC120:GluAUC120, ratio of insulin AUC:glucose AUC from 0 to 120 min of the oral glucose tolerance test; NPS, novel polysaccharide; NPS+S, novel polysaccharide and sitagliptin; PYY, peptide tyrosine tyrosine; S, sitagliptin; ZDF, Zucker diabetic fatty.
and macronutrient absorption (32). It is likely, however, that other actions of S alone and in combination with NPS contributed to the improved glucose control in this study. Both NPS and S contributed to increased lean mass. Skeletal muscle is a major site for glucose disposal in the body (38). The reasons for the increase in lean mass with both NPS and S are likely distinct. The increase in lean mass with NPS or S was achieved in the context of reduced food intake and without significant changes to fat mass. Although we are not aware of any studies that lend insight into the effects of S on lean mass, the increase in overall body weight and lean mass in NPS-treated rats could be related to the increased GIP in these rats. Several lines of evidence suggest that GIP is a key link between overnutrition and obesity, including the finding that dietary fat stimulates GIP secretion and elevated GIP is observed in obesity (5). The recent work by Ugleholdt et al. (39) using GIP receptor (GIPr) expression targeted to white adipose tissue (WAT) or pancreatic b-cells is interesting in this regard. Mice with WAT-targeted GIPr expression had significantly greater weight gain in response to a high-fat diet, which was due to an increase in lean mass rather than fat mass (39). Whether or not the elevated circulating GIP levels observed in our NPS-treated rats are linked to increased lean mass via the GIPr in WAT is not known.

There are several other possible explanations for the seemingly disparate relationship between food intake and body weight gain. It is also possible that alterations in energy expenditure and/or physical activity related to NPS consumption could explain the increase in body weight, but this remains to be measured. Perhaps more likely is that by improving the diabetic state of the rats treated with NPS+S, there was reduced energy loss via the urine due to glucosuria. This is suggested by Sturis et al. (40), who also showed reduced food intake but increased body weight in ZDF rats after 42 d of treatment with the GLP-1 analogue, liraglutide. Similar to our NPS+S-treated rats, the liraglutide-treated rats had lower body weight during the first 10 d of treatment, but with increasing duration, body weight increased despite reduced food intake. Untreated control rats would lose energy via the urine, whereas treatment with liraglutide or NPS+S could potentially reduce this loss.

As expected, active GLP-1 was increased by S (41). This increase in active GLP-1 is the result of the DPP4 inhibitory actions of the drug (42). DPP4 is expressed on the surface of various types of cells, including the kidney, liver, small intestine, and in a soluble form in plasma (25). Whether or not DPP4 activity is correlated with the severity of diabetes is controversial, but Kirino et al. (25) showed that rats fed a high-fat or a high-sucrose diet had higher DPP4 activity in plasma compared with rats fed a control diet. In our study, both NPS and S reduced plasma DPP4 activity, although the effect of S was greater in magnitude than that of NPS. The 38% reduction in plasma DPP4 activity with NPS is nearly identical to the 37% decrease in DPP4 activity observed with the soluble, but low-viscosity fiber oligofructose (27), which leads us to speculate that fermentation end-products of dietary fibers, SCFA, may contribute to the inhibitory effects of soluble fibers to DPP4 activity. While the major action of S is known to be the inhibition of DPP4 activity, recent work by Sangle et al. (43) suggests that S may also exert direct effects on intestinal L cells and act as a GLP-1 secretagogue. In a previous study, we showed that NPS treatment also acted as a GLP-1 secretagogue in the absence of increased GLP-1–immunoreactive L-cell density (17).

Insulin secretion was increased with NPS but not S, a finding reflected in the increased b-cell mass seen with NPS but not S. The long-term presence of type 2 diabetes is characterized by a 40–60% reduction in b-cell mass (44). Early in the development of insulin resistance, b-cell compensation, involving the expansion of b-cell mass and insulin biosynthesis, allows blood glucose levels to remain in the normal range (45). In type 2 diabetes, the classical characteristic of hyperglycemia likely reflects an impaired ability for b-cell compensation (45). In our study, NPS was associated with increased b-cell mass, which may explain in part the improved glucose tolerance in these rats. Indeed, the surrogate indexes of first-phase and total insulin secretion (InsAUC:GluAUC at 0–15 and 0–120 min) were significantly higher with NPS, implicating an improved b-cell function and insulin secretion. Bi et al. (29) showed that InsAUC120:GluAUC30 and InsUC120:GluAUC120 were both re-

![FIGURE 3](https://example.com/figure3.png) Plasma and liver DPP4 activity in obese ZDF rats treated with NPS, S, both, or neither for 6 wk. Values are mean ± SEM, n = 8–11. Labeled means without a common letter differ, P < 0.05. C, control; DPP4, dipeptidyl peptidase 4; NPS, novel polysaccharide; NPS+S; novel polysaccharide and sitagliptin; S, sitagliptin; ZDF, Zucker diabetic fatty.

![FIGURE 4](https://example.com/figure4.png) Photomicrographs of pancreas of obese ZDF rats treated with NPS, S, both, or neither for 6 wk. The bars are 200 μm. The brown-stained tissue is positive for insulin-containing cells within the pancreas. Photographs were selected as representative of the respective treatments. C, control; NPS, novel polysaccharide; NPS+S; novel polysaccharide and sitagliptin; S, sitagliptin; ZDF, Zucker diabetic fatty.
duced in participants with impaired fasting glucose and type 2 diabetes compared with participants with normal glucose tolerance. Given that insulin has been shown to act directly on β-cells in vitro in an autocrine fashion to promote β-cell growth (46), it is plausible that the increased insulin secretion observed in our NPS-treated rats exerted such an effect in vivo. β-Cell expansion is also promoted by GIP (45) and may therefore indicate a role for NPS-induced GIP secretion on increasing β-cell mass in our rats. The reason that S did not produce the same magnitude of insulin response as NPS may be due to the dosage used. We selected a dose of S that is on the low end of the range used in the literature (47–50) but still inhibited ~90% of plasma DDP4 activity 24 h after a single dose (51) in order that we might determine additive effects with NPS, which were identified in other parameters such as blood glucose. Recently, doses of S as high as 300 mg/kg have been examined in ZDF rats (52), which suggests that higher doses of S could be tested in combination with NPS.

Ideally, an insulin tolerance test would also have been performed in our rats to assess insulin sensitivity. We were, however, able to determine the CISI score from the OGTT data. We did not observe any difference in the CISI score among treatments, which is in agreement with our previous work in ZDF rats treated with NPS alone (26). It is possible that NPS increased insulin sensitivity early on in the course of treatment and then dissipated, but this remains to be confirmed.

Similar to previous studies, NPS alone reduced total and LDL cholesterol (17,26). S was also associated with a significant reduction in LDL cholesterol. Several mechanisms have been proposed for the influence of soluble fiber on lipid profile, including interruption of enterohepatic bile acid circulation; alterations in volume, bulk, and viscosity of luminal contents; increases in cholesterol-7α-hydroxylase; and production of SCFA from fermentation (32). Unfortunately, we could not obtain reliable data on serum TG, but it is interesting to note that only the samples from rats treated with NPS+S were low enough following dilution to not exceed the upper limit of the assay. Hepatic steatosis, as measured with Sudan Black staining, was also significantly reduced with NPS and supports the recent finding of reduced hepatic steatosis and serum TG seen in sucrose-fed Sprague-Dawley rats treated with NPS (53). In humans, S was associated with increased LDL cholesterol in patients with type 2 diabetes following 16 wk of treatment (54), which is in contrast to the decrease we observed in our ZDF rats.

Administered separately, dietary interventions and pharmacological treatments can improve metabolic disease and reduce associated health risks. However, as the rates of obesity and type 2 diabetes rise worldwide, there is a growing need to identify effective therapies that maximize the potential benefits, which could be achieved if significant interaction effects occur between the dietary and pharmacological treatment. Our findings suggest that the combined actions of NPS and S markedly reduce glycemia consistently across both acute and long-term measures of glucose response. This novel treatment may be a promising dietary/pharmacological co-therapy for type 2 diabetes management.

**Acknowledgments**

The authors thank Kristine Lee (University of Calgary), Joan Wicks (Alizee), and Jamie Boulet, Lea Rispoli, Harry Maselli, and Jessica Beyenhof (Product Safety Labs) for their technical assistance with this work. PGX and PolyGlycoplexR are registered trademarks of InovoBiologic Inc, Canada. All other trademarks belong to their respective owners. All authors designed research; G.J.G., L.K., R.A.R., and P.J. conducted research; R.A.R., G.J.G., and L.K. analyzed data; R.A.R. wrote the paper; and R.A.R. and S.W. had primary responsibility for final content. All authors read and approved the final manuscript.

**Literature Cited**


**TABLE 3** Serum lipid concentrations and hepatic histology in obese ZDF rats treated with NPS, S, both, or neither for 6 wk

<table>
<thead>
<tr>
<th></th>
<th>C</th>
<th>NPS</th>
<th>S</th>
<th>NPS+S</th>
<th>Diet</th>
<th>Drug</th>
<th>Diet × drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol, mmol/L</td>
<td>5.8 ± 0.4</td>
<td>4.3 ± 0.2</td>
<td>5.8 ± 0.4</td>
<td>3.8 ± 0.2</td>
<td>0.001</td>
<td>0.37</td>
<td>0.39</td>
</tr>
<tr>
<td>LDL cholesterol, mmol/L</td>
<td>4.5 ± 0.3</td>
<td>2.9 ± 0.3</td>
<td>3.3 ± 0.3</td>
<td>2.1 ± 0.1</td>
<td>0.001</td>
<td>0.010</td>
<td>0.52</td>
</tr>
<tr>
<td>HDL cholesterol, mmol/L</td>
<td>2.0 ± 0.1</td>
<td>2.5 ± 0.1</td>
<td>2.0 ± 0.1</td>
<td>2.2 ± 0.1</td>
<td>0.18</td>
<td>0.54</td>
<td>0.51</td>
</tr>
<tr>
<td>Sudan Black staining score</td>
<td>3.1 ± 0.3</td>
<td>2.5 ± 0.2</td>
<td>2.8 ± 0.4</td>
<td>1.8 ± 0.2</td>
<td>0.013</td>
<td>0.08</td>
<td>0.52</td>
</tr>
<tr>
<td>Macrovesicular vacuolation score</td>
<td>0.88 ± 0.13</td>
<td>0.82 ± 0.12</td>
<td>0.89 ± 0.20</td>
<td>0.91 ± 0.09</td>
<td>0.90</td>
<td>0.71</td>
<td>0.78</td>
</tr>
<tr>
<td>Microvesicular vacuolation score</td>
<td>3.1 ± 0.3</td>
<td>2.5 ± 0.2</td>
<td>2.6 ± 0.4</td>
<td>1.8 ± 0.2</td>
<td>0.033</td>
<td>0.036</td>
<td>0.79</td>
</tr>
<tr>
<td>Aspartate aminotransferase, IU/L</td>
<td>102 ± 16.2</td>
<td>60.3 ± 4.92</td>
<td>79.4 ± 5.09</td>
<td>53.4 ± 2.08</td>
<td>0.001</td>
<td>0.06</td>
<td>0.31</td>
</tr>
<tr>
<td>Alanine aminotransferase, IU/L</td>
<td>83.8 ± 4.1</td>
<td>52.4 ± 2.33</td>
<td>60.4 ± 5.81</td>
<td>57.1 ± 3.64</td>
<td>0.016</td>
<td>0.18</td>
<td>0.048</td>
</tr>
</tbody>
</table>

1 Values are means ± SEM, n = 8–11. Labeled means without a common letter differ, P < 0.05. C, control; NPS, novel polysaccharide; NPS+S, novel polysaccharide and sitagliptin; S, sitagliptin; ZDF, Zucker diabetic fatty.


51. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008;325:175–82.

